Mawi iSWAB Microbiome-EL Enables Prime Discoveries’ Development of Rapid Extraction-Less COVID Diagnostic Assay
25.4.2022 16:00:00 EEST | Business Wire | Press release
Mawi DNA Technologies (Mawi), a biotechnology company focusing on the development of innovative technologies for biosampling, announces that Prime Discoveries has successfully developed CovidDetect™, a rapid isothermal amplification diagnostic assay for detecting SARS-CoV-2. Without the need for RNA extraction and purification, the sample result occurs in less than 30 minutes. The assay uses Mawi’s new iSWAB Microbiome-EL (Extraction-Less) sample collection technology. This allows RNA release from the sample and maintains stability, protecting it from degradation and allowing room temperature storage and transport.
Prime Discoveries recently received CE IVD marking for CovidDetect™ and plans to pursue FDA 510K approval soon. Clinical results from Prime CovidDetect™ has been peer reviewed and recently published in PLOS ONE under “A Rapid, Specific, Extraction-Less, and Cost-Effective RT-LAMP Test for the Detection of SARS-CoV-2 in Clinical Specimens.” The CE marking allows deployment of a solution to countries in Africa and Asia where rapid, inexpensive diagnostics for various infections with minimal technical expertise and equipment infrastructure is highly required.
Prime CovidDetect™ leverages Mawi’s unique iSWAB Microbiome-EL sample collection buffer with Prime Discoveries’ patented Loop AMPlification (LAMP) technology. This allows isothermal nucleic acid amplification removing the need for expensive thermal cycling equipment required for PCR. The Extraction-Less protocol bypasses the expensive and complex nucleic acid extraction and purification step, saving 60-90 minutes of sample processing time needed for PCR.
Arun Manoharan, Ph.D., Chief Science Officer at Prime Discoveries, said, “The COVID pandemic has shown that there is a big need for rapid diagnostic assays. Prime Discoveries aims to build a portfolio of solutions which can provide results in under 45 minutes with minimal laboratory, reagent and technical skill requirements. This is ideal for point of care testing in rural neighborhoods, mobile testing, border points of entry and clinical locations with minimal infrastructure. Our work with COVID has shown stable performance of the Mawi iSWAB Microbiome-EL for hundreds of clinical samples with similar or superior performance to RT-PCR solutions. Samples have been stable for more than two weeks with minimal RNA degradation along with high compatibility with our isothermal nucleic acid amplification techniques.” He added, “Our partnership with Mawi enables Prime Discoveries to develop room temperature sampling with Extraction-Less capabilities for our rapid diagnostic solutions in many areas. These include influenza, chlamydia, gonorrhea, trichomonas, HBV, HCV, HPV, TB, herpes, syphilis, etc. We are excited to partner with Mawi for future products empowering customers to test thousands of patients rapidly for various infections including respiratory, gastrointestinal, sexually transmitted pathogens and those with anti-microbial resistance.”
About Prime Discoveries
Prime Discoveries develops rapid, novel diagnostics for emerging pathogen infections with a focus on cost effective, massively scalable and easily automatable assays. Founded in NYC in 2017, Prime’s scientists have extensive backgrounds in microbiology, computational biology, lab automation and AI from Genentech, Cooper Genomics, Recombine, Phosphorus, and NYU. Prime is advised by leading experts in the fields of genomics and public health including Dr. George Church and New York University. Prime is supported by academic institutions, venture capital firms and angel investors including New York University, Charles Zegar (Bloomberg), Esther Dyson (23 & Me), BoxGroup, Akron Fusion Ventures, Beresford Ventures, Cannonball Capital, Liquid 2 Ventures, Francois Nader (Moderna, Acceleron, Shire), Unshackled Ventures, Doberman Forward, and others. For more information, visit www.primediscoveries.com.
About Mawi DNA Technologies
Mawi DNA Technologies, founded in 2013, has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. Mawi’s mission is to uphold sample integrity from anywhere in the world at room temperature, enabling true sample diversity across any geography or population segment. At Mawi, The Future of Biosampling is Here™. For more information, visit http://www.mawidna.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005323/en/
Contact information
Investors:
Jerome David, VP of Sales and Marketing
510-256-5186, j.david@mawidna.com
Media Contact:
Susan Tellem, APR, RN, BSN
310-313-3444, susan@tellemgrodypr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting Enters Into Collaboration Agreement With Alfa Group5.2.2026 16:30:00 EET | Press release
Andersen Consulting adds depth to its cybersecurity offering with collaborating firm Alfa Group, a leading technology firm with nearly three decades of experience helping organizations safeguard and optimize their operations. Founded in 1996 and headquartered in Rome, Alfa Group delivers advanced solutions in cybersecurity, fraud detection and prevention, incident response, and vulnerability management, as well as select business process management services. Its proprietary technology, N.O.V.A., is an end-to-end managed service that integrates Alfa Group’s innovations with third-party systems to safeguard digital infrastructures, mitigate risk, and enhance operational efficiency. The firm serves clients across industries including finance and insurance, defense and aerospace, telecom, manufacturing, energy, and pharmaceutical. "Our collaboration with Andersen Consulting allows us to extend our reach and deliver greater value to clients navigating the complexities of digital transformat
Duna, Built by Stripe Veterans, Raises €30 Million CapitalG-led Series A to Solve Business Identity For The Internet5.2.2026 16:00:00 EET | Press release
Duna, the identity fintech founded by two Stripe alumni, today announced a €30 million Series A funding round led by CapitalG, Alphabet’s independent growth fund. Existing investors Index Ventures, Puzzle Ventures and Snowflake Chairman Frank Slootman also participated in the round. The company, based in Germany and the Netherlands, was launched in 2023 by Duco van Lanschot, who was head of Benelux and DACH at Stripe for three years, and David Schreiber, who spent six years at Stripe where he ran the company’s largest global business unit, including the core card payment platform. In May 2025, the company announced a €10.7 million seed round led by Index Ventures. The latest fundraise brings Duna’s total funding to more than €40 million. Duna’s mission is to build global trust infrastructure by providing a digital passport for every business. Over time, this will evolve into a network for shareable identity and one-click onboarding. Today Duna’s AI-native business identity platform ser
AI-Powered Experian Assistant for Model Risk Management Wins 2026 BIG Innovation Award5.2.2026 16:00:00 EET | Press release
Experian today announced that its recently launched, AI‑powered Experian Assistant for Model Risk Management has been awarded the 2026 BIG Innovation Award in the Innovative Products category. Recognizing trailblazers across industries since 2014, this global award celebrates exceptional innovation and the value it brings to a recipient’s clients, stakeholders and community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260205042051/en/ Experian's recently launched, AI-powered Experian Assistant for Model Risk Management has been awarded the 2026 BIG Innovation Award in the Innovative Products category. Fully integrated into the Experian Ascend Platform™ and powered by ValidMind technology, Experian Assistant for Model Risk Management helps accelerate model validation, improve auditability and reduce regulatory risk. By offering standardized templates, centralized documentation and streamlined workflow approvals, the soluti
LTIMindtree Recognized as a Leader in Everest Group Payments IT Services PEAK Matrix® Assessment 20255.2.2026 15:30:00 EET | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a leading global technology consulting and digital solutions provider, has been positioned as a Leader in the Everest Group Payments IT Services PEAK Matrix® Assessment 2025. This recognition is for being a strategic transformation partner that combines modernization scale, platform alliances, and innovation across real-time, digital assets, and ensure secure, regulator-ready payment environments. Everest Group highlighted LTIMindtree’s strong market impact and vision and capability in delivering largescale payments across issuers, acquirers, payment processors, card networks, and FinTechs. The assessment comes at a time when enterprises are rapidly modernizing legacy payments platforms to support real-time, cross-border, and ISO 20022 compliant payment environments, while enhancing resiliency, interoperability, and regulatory compliance. LTIMindtree stands out for its product engineering expertise across major payment platforms like Finastra GPP/P
Visby Medical Collaborates with Watchmaker Genomics to Enhance Respiratory Pathogen Detection in the At-Home Setting5.2.2026 15:00:00 EET | Press release
Visby Medical, a leading innovator in at-home PCR testing of infectious diseases, has announced a strategic collaboration with Watchmaker Genomics, a supplier of innovative products for molecular analysis, to develop next-generation diagnostic tests for respiratory pathogen detection in the at-home setting. This partnership pairs Visby Medical’s instrument-free PCR testing technology – the first and only of its kind – with Watchmaker’s expertise in engineering enzymes to address application-specific performance gaps. Clinical samples collected from patients for at-home testing are typically unprocessed, making them vulnerable to molecular inhibitors that can reduce signal strength and lower assay sensitivity. The need for rapid results in the at-home setting also places unique performance demands on the assays and the enzymes they rely on. “Recent increases in COVID cases involving new strains and the current flu season highlight the need for tests that are reliable and fast,” explaine
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom